Moderna's Flu Shot Under FDA Review; J&J Stays Focused on Cancer
As the FDA reviews Moderna's flu shot, Johnson & Johnson has decided against entering the obesity market, choosing to prioritize cancer treatments instead.
Editorial Staff
1 min read
Updated 1 day ago
The FDA is currently reviewing Moderna's flu shot, a development that could have significant implications for public health.
In a strategic move, Johnson & Johnson has opted not to pursue opportunities in the rapidly growing obesity market.
Instead, the company has reaffirmed its commitment to focusing on cancer-related diseases, aligning its resources with its long-term goals.